Evidence map›Paper›PMID 42788016›Full record

ArticleCureus2026

A Case of Duodenal Metastasis From a Poorly Differentiated Lung Carcinoma.

Caroline Meurer Da Cunha, Sebastian Hernandez Mejia, Svetoslav Bardarov

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Caroline Meurer Da CunhaInternal Medicine, Richmond University Medical Center, New York, USA.
Sebastian Hernandez MejiaInternal Medicine/Cardiology, Richmond University Medical Center, New York, USA.
Svetoslav BardarovPathology and Laboratory Medicine, Richmond University Medical Center, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the leading causes of cancer-related mortality worldwide and commonly metastasizes to the brain, bones, liver, and adrenal glands, whereas gastrointestinal (GI) involvement is uncommon and rarely diagnosed during a patient's lifetime. We report a rare case of poorly differentiated carcinoma of the lung with duodenal metastasis. The patient was a 73-year-old man who presented with abdominal pain and melena, prompting esophagogastroduodenoscopy (EGD), which revealed ulcerated duodenal lesions. Histopathologic examination of the duodenal biopsy demonstrated a poorly differentiated carcinoma morphologically similar to the known lung tumor. Immunohistochemical analysis showed positivity for pancytokeratin (AE1/AE3) and PD-L1, with negative staining for TTF-1, CK7, CDX2, CK5/6, p63, neuroendocrine markers, and lymphoid markers, supporting metastatic disease when considered alongside the patient's known primary lung malignancy and clinicopathologic findings. As the lesions were neither actively bleeding nor causing obstruction, no endoscopic or surgical intervention was required. Despite initiation of oncologic therapy, the patient's condition rapidly deteriorated, and he died during the same hospitalization. The interval from diagnosis of the primary lung tumor to identification of GI involvement was only two months, followed by a further survival of 28 days after identification of duodenal involvement. This report underscores the importance of maintaining a high index of suspicion for GI metastases in patients with lung cancer who develop GI symptoms, as timely recognition may facilitate appropriate diagnostic evaluation and management.

Indexed as

ca lungduodenum metastasisgastro-intestinal metastasisprimary lung carcinomarapid progression

Identifiers

PMID42788016
PMCPMC13602839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.